A new toxicology report tied to AbbVie’s development of a bifunctional protein degrader molecule describes unusual liver findings during dog studies, flagging bile-duct degeneration and necrosis after repeat dosing. The paper describes pathology effects that were not limited to standard liver-enzyme elevations, even though blood enzymes were reported as normal. The candidate, referred to only as “Compound X” in the disclosure, was being developed as a clinical-stage degrader aimed at a kinase target. In the described regimen, animals received 30 mg/kg daily for five days and developed marked liver trouble. Histopathology reportedly showed vacuoles and debris in cholangiocytes, with bile-duct damage described as highly unusual relative to commonly observed tox profiles in similar programs. The report serves as an internal mechanistic red flag for teams working in high-molecular-weight, bifunctional degrader chemical space. For development strategists, the key issue is not just whether a dose-limiting tox occurred, but how the pattern of organ injury complicates dose selection, candidate optimization, and the ability to predict human risk from preclinical models.